Страна: Ирландия
Язык: английский
Источник: HPRA (Health Products Regulatory Authority)
Chlortetracycline hydrochloride
Interchem Ireland Ltd
QJ01AA03
Chlortetracycline hydrochloride
150 milligram(s)/gram
Oral powder
POM: Prescription Only Medicine as defined in relevant national legislation
Cattle
chlortetracycline
Antibacterial
Authorised
2001-06-29
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT RESPICHLOR 15% w/w Oral Powder. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each g contains Active substance Chlortetracycline hydrochloride 150 mg For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Oral Powder. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Calves (less than 6 months of age). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES The product is indicated as an aid in the treatment of respiratory disease in calves caused by_ Pasteurella spp_., sensitive to chlortetracycline. 4.3 CONTRAINDICATIONS Do not use in adult ruminants, dairy cows and veal calves. Do not use in animals with known hypersensitivity to the active ingredient. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _3_ _0_ _/_ _1_ _1_ _/_ _2_ _0_ _1_ _6_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _4_ _9_ _7_ _7_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Ideally, use of the product should be based on susceptibility testing. Inappropriate use of the product may increase the prevalence of bacteria resistant to chlortetracycline and may decrease the effectiveness of treatment with related substances, due to the potential for cross-resistance. To ensure the correct dosage and to avoid possible under-dosing, the bodyweight should be determined as accurately as possible SPECIAL PRECAUTIONS TO BE TAKEN BY Прочитать полный документ